RT @AMRActionFund: Great to see our portfolio company @antabio highlighted here as being "well-positioned to advance its pipeline and cont….

RT @lespepitestech: Bravo 👏 à ces startups françaises qui ont réussi à lever 506.6 millions d'euros la semaine dernière 🚀💵 😍. Voici le top….

RT @IrdiCapital__I: * Rise and shine * 📍#Toulouse. À l’aube de révolutions médicales apportant du soin, de meilleures prises en charge mais….

RT @B3Cnewswire: ANTABIO Raises €25 million in Series B Financing. The financing will be used to support the clinical development of MEM-AN….

RT @PierrickMerlet: #Santé : Antabio boucle une série B majeure pour commercialiser son premier traitement via @LaT….

RT @AMRActionFund: We are thrilled to welcome @antabio to our portfolio. Learn more about the company's €25 million Series B round: https:/….

@antabio announces dosing of the first subjects in its Phase 1 clinical trial of MEM-ANT3310, a next generation treatment of hospital infections caused by carbapenem-resistant Acinetobacter baumannii (#CRAB) and carbapenem-resistant Enterobacterales (#CRE).

Check our new paper on the chemical optimization & initial evaluation in cellular & animal models of @antabio's #Pseudomonas #aeruginosa #LasB inhibitors. An international collaboration based on a work initially funded by @wellcometrust & @CARB_X .

RT @JohnRex_NewAbx: The recent announcement of 🇫🇷's #ARPEGE_AMR is exciting stuff! The idea of additional economic thinking is a welcome ad….

RT @CARB_X: Following the #GRAMReport @TheLancet Dr. Peter Bak @BBLifeScience & CEO @MLantabio @antabio discuss the #global #health threat….

RT @SGPI_avenir: #Pépite | Félicitations à @antabio @biomerieux @CHUdeLyon @TSEinfo dont le consortium vient d’obtenir 9 M€ du #PIA pour lu….

French multidisciplinary consortium to fight #antimicrobialresistance awarded close to €9m public funding. Led by @antabio with @biomerieux @CHUdeLyon & @TSEinfo, #ARPEGE_AMR to address #AMR via preventive, diagnostic, therapeutic & economic approaches

Le consortium français ARPEGE obtient un financement public de près de 9 millions d’euros pour combattre l’antibiorésistance. Porté par @antabio, ce projet pluridisciplinaire financé par le #PIA est mené conjointement avec @biomerieux @CHUdeLyon & @TSEinfo

RT @IsabelleSaves1: IL EST ENCORE TEMPS DE VOUS INSCRIRE ! Colloque sur la #mucoviscidose co-organisé par @abc_muco @CHUdeToulouse @IpbsTou….

Meet @antabio at #ECCMID2021 . ✅#Poster3147 Interaction of the new β-lactamase inhibitor ANT3310 with clinically relevant β-lactamases. ✅#Poster4372 Structural & biochemical characterisation of ANT3273, a novel antivirulence compound, with Pseudomonas aeruginosa LasB elastase

👋New @antabio paper out: .ANT2681 restores meropenem activity vs NDM+ carbapenem-resistant Enterobacterales to clinically useful levels. Compares favorably vs comparator drugs and is also active vs NDM-PBP3 mutants. .#NDM #CRE #MBLI #WHOcriticalpriority.

RT @AllianceBEAM: Our very own @MLantabio will chair today’s JPIAMR Therapeutics Workshop, intended to probe the gaps and opportunities in….

@antabio reçoit le soutien de la Région @Occitanie pour développer son nouveau traitement contre les infections multirésistantes. 886K€ au titre du Contrat Innovation Région attribués pour le dév de ANT3310-MEM, un produit destiné à lutter contre les infections respiratoires.

New @antabio paper out: the discovery of a novel and tractable series of Pseudomonas aeruginosa elastase (LasB) inhibitors. Supported by @wellcometrust and @CARB_X. #cysticfibrosis #PEi #LasB #Inhaled #LungInfections

📰New @antabio paper is out: #ANT3310 a new broad-spectrum SBLi that strongly potentiates Meropenem vs CRE & CR Acinetobacter baumannii. 👏We thank our co-authors @unisiena @gvkbio @_IHMA_ @Evotec @CRiverLabs .▶️#AMR #antimicrobialresistance #StopSuperbugs